A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis.

Authors :: Deng G
Fu L
Source :: The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Sep; Vol. 24 (9), pp. 940-941. Date of Electronic Publication: 2024 May 17.
Publication Year :: 2024
Abstract: Competing Interests: We declare no competing interests. We acknowledge Gao Yuan from Beijing You'An Hospital for his assistance with our manuscript.

Subjects :: Humans
Nitroimidazoles therapeutic use
Drug Therapy, Combination
Mycobacterium tuberculosis drug effects
Tuberculosis drug therapy
Moxifloxacin therapeutic use
Antitubercular Agents therapeutic use
Diarylquinolines therapeutic use
Pyrazinamide therapeutic use
Tuberculosis, Multidrug-Resistant drug therapy
Fluoroquinolones therapeutic use
Fluoroquinolones pharmacology

Full Text Access

Tools